25/100BRoivant Sciences reports its Q3 FY2027 results on 5 February 2027, before the market opens. Analysts expect earnings per share of -0.31 USD and revenue of 37.83M USD.
In Q2 FY2027, reported on 9 November 2026, Roivant Sciences reported EPS of -0.27 USD against the -0.37 USD analysts expected (+26.4%), on revenue of 35.12M USD against 4.34M USD (+710.0%).
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth | Next-day move |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 FY2027 | -0.31 | — | — | — | 66.05M | — | — | +2,521.20% | — | |
| Q3 FY2027 | -0.31 | — | — | — | 37.83M | — | — | +1,792.49% | — | |
| Q2 FY2027 | -0.37 | -0.27 | +26.36% | — | 4.34M | 35.12M | +709.96% | +2,135.58% | — | |
| Q1 FY2027 | -0.30 | -0.33 | -10.14% | — | 2.06M | 1.44M | -29.89% | -33.55% | +1.5% | |
| Q4 FY2026 | -0.29 | -0.28 | +3.49% | — | 3.41M | 2.52M | -26.20% | -66.71% | +14.9% | |
| Q3 FY2026 | -0.30 | -0.24 | +19.88% | — | 5.08M | 2.00M | -60.65% | -77.83% | +22.3% | |
| Q2 FY2026 | -0.32 | -0.20 | +36.86% | — | 5.62M | 1.57M | -72.04% | -64.89% | — | |
| Q1 FY2026 | -0.25 | -0.25 | -0.82% | -309.79% | 7.30M | 2.17M | -70.28% | -96.06% | — | |
| Q4 FY2025 | -0.26 | -0.29 | -10.05% | — | 54.07M | 7.57M | -86.00% | -73.83% | — | |
| Q3 FY2025 | -0.25 | -0.23 | +9.04% | — | 5.00M | 9.02M | +80.36% | -75.72% | — | |
| Q2 FY2025 | -0.25 | -0.29 | -17.41% | — | 45.92M | 4.48M | -90.26% | -87.94% | — | |
| Q1 FY2025 | -0.24 | 0.12 | +149.32% | — | 30.72M | 55.13M | +79.47% | +154.96% | — | |
| Q4 FY2024 | -0.26 | -0.23 | +12.99% | — | 31.01M | 28.93M | -6.70% | +5.68% | — | |
| Q3 FY2024 | -0.31 | -0.21 | +32.04% | — | 31.77M | 37.14M | +16.89% | +117.80% | — | |
| Q2 FY2024 | -0.28 | -0.26 | +7.14% | — | 27.11M | 37.10M | +36.88% | +196.03% | +2.7% | |
| Q1 FY2024 | -0.30 | -0.38 | -26.67% | — | 24.49M | 21.62M | -11.69% | +400.67% | +1.1% | |
| Q4 FY2023 | -0.41 | -0.20 | +51.22% | — | 18.17M | 27.38M | +50.69% | +196.82% | +11.0% | |
| Q3 FY2023 | -0.36 | -0.49 | -36.11% | — | 14.78M | 17.05M | +15.40% | -29.95% | +1.6% | |
| Q2 FY2023 | -0.41 | -0.42 | -2.44% | — | 5.70M | 12.53M | +119.85% | -10.40% | +2.9% | |
| Q1 FY2023 | -0.30 | -0.48 | -60.00% | — | 7.18M | 4.32M | -39.83% | — | -3.6% | |
| Q4 FY2022 | -0.25 | -0.39 | -56.00% | — | 13.35M | 9.22M | -30.90% | — | 0.0% | |
| Q3 FY2022 | -0.23 | -0.41 | -78.26% | — | 9.87M | 24.34M | +146.72% | — | +5.8% | |
| Q2 FY2022 | -0.45 | -0.26 | +42.22% | — | 7.22M | 13.99M | +93.66% | — | -3.2% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2029 | -0.61 | — | — | — | 1.57B | — | — | +170.70% |
| FY2028 | -1.18 | — | — | — | 581.17M | — | — | +380.42% |
| FY2027 | -1.23 | — | — | — | 120.97M | — | — | +1,364.53% |
| FY2026 | -1.12 | -0.97 | +13.24% | — | 9.09M | 8.26M | -9.11% | -89.16% |
| FY2025 | -0.52 | -0.69 | -32.50% | — | 141.38M | 76.20M | -46.11% | -38.94% |
| FY2024 | 5.22 | -1.08 | -120.68% | — | 181.74M | 124.80M | -31.33% | +103.65% |
| FY2023 | -1.59 | -1.59 | -0.14% | — | 52.28M | 61.28M | +17.22% | — |
The move is the shares' change on the trading day after the report: after a report after the close, the next day's close on the report day's; before the open, the report day's close on the day before's. Surprise is the reported figure against the analysts' average estimate.
From the last earnings call, the company's guidance and analysts' previews, and checked against the report when it comes.
Early sales will show whether Roivant can turn its newly approved medicine into a meaningful business.
The loss will show how much drug development and the new medicine's launch are costing the company.
On average, analysts' EPS estimate was 27.4% off the result, either way, and their revenue estimate 110.7%, over the last 12 quarters.
See also:Forecast,EPS,Income statement
Source: Financial Modeling Prep
We value your privacy
We use cookies to enhance your experience and analyze site traffic. By continuing, you agree to our use of cookies. Privacy Policy
